Search Results - covid-19

6 Results

Sort By:

Summary: The NCI seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA. Description of Technology: Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): G Esta Sterneck, Dipak Poria

Keywords(s): COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration

Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method

Summary: Inventors at the National Eye Institute are seeking research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Bin Guan, Robert Hufnagel

Keywords(s): Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus

Category(s): TherapeuticArea > Oncology, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Therapeutics Against Pathogenic Coronaviruses

Summary: Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty

Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Summary: The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections. Description of Technology: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Summary: The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies. Description of Technology: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)

The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...

Published: 10/28/2024 | Updated: 12/6/2022 | Inventor(s): Qi Zhang, Wei Zheng, Catherine Chen, Yihong Ye

Keywords(s): COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics